Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: A prospective randomised controlled trial (RCT)

Human Reproduction

Volumn 25, Issue 3, 2010, Pages 683-689

  Lainas, Trifon G ^a   Sfontouris, Ioannis A ^a   Zorzovilis, Ioannis Z ^a   Petsas, George K ^a   Lainas, George T ^a   Alexopoulou, Efthymia ^b   Kolibianakis, Efstratios M ^c  

^a Eugonia Iatriki Erevna IVF Centre   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

GnRH agonists; GnRH antagonists; Ovarian hyperstimulation syndrome; Polycystic ovary syndrome; Pregnancy rates

Indexed keywords

ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS GESTODENE; GANIRELIX; GESTODENE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; RECOMBINANT FOLLITROPIN; TRIPTORELIN;

ADULT; ARTICLE; BLEEDING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DOWN REGULATION; DRUG WITHDRAWAL; FEMALE; FERTILIZATION IN VITRO; HUMAN; INCIDENCE; LIVE BIRTH; MAJOR CLINICAL STUDY; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; PROBABILITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

EID: 76749141766     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dep436     Document Type: Article

References (25)

1. Aboulghar MA, Mansour RT, Amin YM, Al-Inany HG, Aboulghar MM, Serour GI. A prospective randomized study comparing coasting with GnRH antagonist administration in patients at risk for severe OHSS. Reprod Biomed Online 2007;15:271-279.
2. Bahceci M, Ulug U, Ben-Shlomo I, Erden HF, Akman MA. Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study. J Reprod Med 2005;50:84-90.
3. Barash A, Weissman A, Manor M, Milman D, Ben-Arie A, Shoham Z. Prospective evaluation of endometrial thickness as a predictor of pituitary down-regulation after gonadotropin-releasing hormone analogue administration in an in vitro fertilization program. Fertil Steril 1998;69:496-499.
4. Delvigne A, Demoulin A, Smitz J, Donnez J, Koninckx P, Dhont M, Englert Y, Delbeke L, Darcis L, Gordts S et al. The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. I. Clinical and biological features. Hum Reprod 1993;8: 1353-1360. (Pubitemid 23265961)
5. Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91: 48-53. (Pubitemid 43069116)
6. Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv 1989;44:430-440.
7. Griesinger G, Diedrich K, Tarlatzis BC, Kolibianakis EM. GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis. Reprod Biomed Online 2006; 13:628-638.
8. Heijnen EM, Eijkemans MJ, Hughes EG, Laven JS, Macklon NS, Fauser BC. A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. Hum Reprod Update 2006; 12:13-21.
9. Hohmann FP, Macklon NS, Fauser BC. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. J Clin Endocrinol Metab 2003; 88:166-173.
10. Hwang JL, Seow KM, Lin YH, Huang LW, Hsieh BC, Tsai YL, Wu GJ, Huang SC, Chen CY, Chen PH et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: a prospective randomized study. Hum Reprod 2004;19: 1993-2000.
11. Kolibianakis E, Zikopoulos K, Albano C, Camus M, Tournaye H, Van Steirteghem A, Devroey P. Reproductive outcome of polycystic ovarian syndrome patients treated with GnRH antagonists and recombinant FSH for IVF/ICSI. Reprod Biomed Online 2003;7: 313-318.
12. Kolibianakis E, Albano C, Zikopoulos K, Kahn JA, Van Steirteghem A, Devroey P. GnRH antagonists in poor responders. Acta Obstet Gynecol Scand 2004;83:1216-1217.
13. Kolibianakis EM, Collins J, Tarlatzis BC, Devroey P, Diedrich K, Griesinger G. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Hum Reprod Update 2006;12:651-671.
14. Kolibianakis EM, Kalogeropoulou L, Griesinger G, Papanikolaou EG, Papadimas J, Bontis J, Tarlatzis BC. Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysis. Hum Reprod Update 2007a; 13:445-452.
15. Kolibianakis EM, Papanikolaou EG, Tournaye H, Camus M, Van Steirteghem AC, Devroey P. Triggering final oocyte maturation using different doses of human chorionic gonadotropin: a randomized pilot study in patients with polycystic ovary syndrome treated with gonadotropin-releasing hormone antagonists and recombinant follicle-stimulating hormone. Fertil Steril 2007b;88:1382-1388.
16. Kurzawa R, Ciepiela P, Baczkowski T, Safranow K, Brelik P. Comparison of embryological and clinical outcome in GnRH antagonist vs. GnRH agonist protocols for in vitro fertilization in PCOS non-obese patients. A prospective randomized study. J Assist Reprod Genet 2008; 25:365-374.
17. Lainas T, Zorzovilis J, Petsas G, Stavropoulou G, Cazlaris H, Daskalaki V, Lainas G, Alexopoulou E. In a flexible antagonist protocol, earlier, criteria-based initiation of GnRH antagonist is associated with increased pregnancy rates in IVF. Hum Reprod 2005;20:2426-2433.
18. Lainas TG, Petsas GK, Zorzovilis IZ, Iliadis GS, Lainas GT, Cazlaris HE, Kolibianakis EM. Initiation of GnRH antagonist on Day 1 of stimulation as compared to the long agonist protocol in PCOS patients. A randomized controlled trial: effect on hormonal levels and follicular development. Hum Reprod 2007;22:1540-1546.
19. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992;58:249-261.
20. Orvieto R, Nahum R, Meltcer S, Homburg R, Rabinson J, Anteby EY, Ashkenazi. Ovarian stimulation in polycystic ovary syndrome patients: the role of body mass index. Reprod Biomed Online 2009;18: 333-336.
21. Ragni G, Vegetti W, Riccaboni A, Engl B, Brigante C, Crosignani PG. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome. Hum Reprod 2005;20:2421-2425.
22. Rizk B, Aboulghar MA. Classification, pathophysiology and management of ovarian hyperstimulation syndrome. In Brinsden P (ed). In-Vitro Fertilization and Assisted Reproduction. New York, London: The Parthenon Publishing Group, 1999, 131-155
23. The Practice Committee of the American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril 2004;82:81-86
24. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-47
25. The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 2008;89:505-522.